Mesoderm and definitive endoderm cell populations

Patent metadata

Field	Value
Publication number	US-9745553-B2
Application number	US-201615067728-A
Country	US
Kind code	B2
Filing date	Mar 11, 2016
Priority date	Jun 24, 2005
Publication date	Aug 29, 2017
Grant date	Aug 29, 2017

Abstract

The present invention provides cell populations that are enriched for mesendoderm and mesoderm, and cell populations that are enriched for endoderm. The cell populations of the invention are useful for generating cells for cell replacement therapy. The present invention further provides a method of generating hepatocytes, cell populations enriched for hepatocytes, and a method of hepatocyte replacement therapy.

First claim

The invention claimed is:

1. A method of making a cell population enriched for hepatocytes comprising the steps of (a) culturing pluripotent stem cells in the presence of activin to induce differentiation into endoderm lineages, (b) further culturing the cells of step (a) in the presence of BMP-4 and bFGF and in the absence of serum to induce differentiation into a hepatic lineage, and (c) culturing the cells from step (b) with one or more cytokines that promote hepatocyte growth to produce a population enriched for hepatocytes.

2. The method of claim 1 wherein the cells are human cells.

3. The method of claim 1 where activin is present at a concentration of about 30 ng/ml to about 100 ng/ml.

4. The method of claim 1 wherein activin is present at a concentration of about 50 ng/ml.

5. The method of claim 1 wherein BMP-4 is present at a concentration of about 10 ng/ml to about 30 ng/ml.

6. The method of claim 1 wherein BMP-4 is present at a concentration of about 30 ng/ml.

7. The method of claim 1 wherein bFGF is present at a concentration of about 1.0 ng/ml to about 10 ng/ml.

8. The method of claim 1 wherein bFGF is present at a concentration of about 10 ng/ml.

9. The method of claim 1 wherein the cytokines are selected from the group consisting of VEGF, human recombinant HGF, EGF, bFGF, and TGFalpha.

10. The method of claim 9 wherein VEGF is present at a concentration of about 10 ng/ml.

11. The method of claim 9 wherein human recombinant HGF is present at a concentration of about 20 ng/ml.

12. The method of claim 9 wherein EGF is present at a concentration of about 10 ng/ml.

13. The method of claim 9 wherein bFGF is present at a concentration of about 10 ng/ml.

14. The method of claim 9 wherein TGFalpha is present at a concentration of about 20 ng/ml.

Assignees

• Icahn School Med Mount Sinai

Inventors

• Keller Gordon
• Gadue Paul

Classifications

• A61P7/00

  Drugs for disorders of the blood or the extracellular fluid · CPC title

• A61P9/00

  Drugs for disorders of the cardiovascular system · CPC title

• A61P3/10

  for hyperglycaemia, e.g. antidiabetics · CPC title

• A61P19/00

  Drugs for skeletal disorders · CPC title

• A61P1/16

  for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics · CPC title